Iwasa, Satoru
Kudo, Toshihiro
Takahari, Daisuke
Hara, Hiroki
Kato, Ken
Satoh, Taroh
Article History
Received: 12 December 2019
Accepted: 16 April 2020
First Online: 29 April 2020
Change Date: 22 June 2020
Change Type: Correction
Change Details: The article Practical guidance for the evaluation of disease progression.
Conflict of interest
: Satoru Iwasa has received research grants from Chugai Pharmaceutical, Bayer Yakuhin, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, and Merck Biopharma, and honoraria from Ono Pharmaceutical, Eli Lilly, Taiho Pharmaceutical and Chugai Pharmaceutical. Toshihiro Kudo has received donations for his department from Yakult Honsha, Chugai Pharmaceutical, and Ono Pharmaceutical, research grants from Eli Lilly, Bayer Yakuhin, and Otsuka Pharmaceutical, and honoraria from Yakult Honsha, Chugai Pharmaceutical, Ono Pharmaceutical, Eli Lilly, Bayer Yakuhin, Merck Biopharma, MSD, Takeda Pharmaceutical, Taiho Pharmaceutical and Sanofi. Daisuke Takahari has received honoraria from Ono Pharmaceutical, Bristol Myers Squibb, Eli Lilly, Taiho Pharmaceutical and Chugai Pharmaceutical. Hiroki Hara has received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Eli Lilly, Chugai Pharmaceutical, Yakult Honsha, Takeda Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo, Sanofi and MSD. Ken Kato has received research grants from Ono Pharmaceutical, MSD, Shionogi, Merck Biopharma and BeiGene. Taroh Satoh has received donations for his department from Ono Pharmaceutical, Yakult Honsha and Chugai Pharmaceutical, and research grants and honoraria from Ono Pharmaceutical, Yakult Honsha, Chugai Pharmaceutical, Eli Lilly, Bristol Myers Squibb, Merck Serono, Takeda Pharmaceutical, Taiho Pharmaceutical and MSD.